Endometriosis-related Pain
Conditions
Keywords
Endometriosis, Chronic pain, Transcutaneous electrical nerve stimulation
Brief summary
The study evaluates the effect of TENS (transcutaneous electrical nerve stimulation) as add-on treatment compared with conventional analgesic treatment in patients with endometriosis-related chronic pain. Patients with frequent pain and high pain intensity will be randomized to additional treatment with TENS or conventional treatment for 8 weeks to evaluate the acute effects of TENS treatment (n=40). Patients with endometriosis-related pain that is not frequent or without high pain intensity constitute an external control group. All patients in the study will receive TENS treatment for a total of 16 weeks, for evaluation of long-term effects of TENS treatment.
Detailed description
Endometriosis affects approximately one in ten women of childbearing age and may involve both acute pain related to the menstrual cycle and chronic pain. Usual analgesic therapy is often inadequate and/or involves unacceptable side effects and risks with long-term use. Transcutaneous electrical nerve stimulation (TENS) is a patient controlled treatment for pain relief with few side-effects. To date there is limited knowledge of how TENS treatment should be carried out for optimal pain relief in this patient group. The aim of the study is asses the effect of TENS as add-on treatment compared with conventional analgesic treatment in patients with endometriosis-related chronic pain. Patients with frequent pain and high pain intensity (≥ 4 according to Numeric Rating Scale, NRS) will be randomized to additional treatment with TENS or conventional treatment for 8 weeks in order to evaluate the acute effects of TENS treatment (n=40). Patients with endometriosis-related pain that is not frequent or without high pain intensity constitute an external control group. All patients in the study will receive TENS treatment for a total of 16 weeks, for evaluation of long-term effects of TENS treatment in chronic endometriosis-related pain. Prior to start of TENS treatment, all patients receive education on chronic endometriosis-related pain and TENS treatment. Study participants will be asked to participate in a qualitative follow-up within the study including a semi-structured individual interview (n=10-15) before intervention and a semi-structured focus group (n=9-15) interview after completion of TENS treatment.
Interventions
DEVICETranscutaneous electrical nerve stimulation (TENS)
Treatment with transcutaneous electrical nerve stimulation (TENS) during 16 weeks.
OTHERConventional analgesic treatment
Conventional analgesic treatment. Conventional analgesic treatment may include no pharmacological treatment if the patient does not use any analgesics.
Sponsors
Vastra Gotaland Region
Göteborg University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Patients with frequent pain and high pain intensity (≥ 4 according to Numeric Rating Scale, NRS) will be randomized to additional treatment with TENS or conventional analgesic treatment for 8 weeks in order to evaluate the acute effects of TENS treatment (n=40). Patients with endometriosis-related pain that is not frequent or without high pain intensity constitute an external control group. All patients in the study will receive TENS treatment for a total of 16 weeks, for evaluation of long-term effects of TENS treatment in chronic endometriosis-related pain.
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* Age ≥18 years * Consents to participation in the study * Verified endometriosis (by laparoscopy or ultrasound). * Chronic endometriosis-related pain (\> 3 months), available for TENS treatment * Functioning, stable endometriosis-specific hormonal drug therapy. The endometriosis-specific drug therapy must be unchanged for the last 3 months and no gynecological surgical procedures for the treatment of endometriosis are planned during the next 7 months (during study participation). The endometriosis-specific drug therapy does not refer to analgesic therapy for symptom relief of endometriosis-related pain.
Exclusion criteria
* Patient with inability to understand and use written and spoken Swedish * Patient with pacemaker and/or ICD or other electronic implants * Patient with impaired sensation over the painful area * Malignant disease with an expected survival \<12 months * Alcohol or substance abuse * Serious untreated psychiatric illness and/or psychological condition that is the primary determinant of the patient's condition * Participating in another intervention study with possible impact on current study outcome measures * Patient who is using \>90 morphine equivalents/day * Patient who is electro-acupuncture * Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pain intensity | 8 weeks after randomization | Pain intensity according to numeric rating scale (score from 0 to 10, where 0 is described as no pain and 10 as worst pain imaginable) with regard to endometriosis-related chronic pain |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in pain intensity | 8 weeks after randomization | Pain intensity according to numeric rating scale (score from 0 to 10, where 0 is described as no pain and 10 as worst pain imaginable) with regard to endometriosis-related chronic pain, Likert scale (1= worse, 2= unchanged, 3= slightly improved, 4= much improved, 5 = very much improved,and 6= completely improved). |
| Health Related Quality of Life (HRQL) assessed with EHP 30 | 8 weeks after randomization | Assessed with Endometriosis Health Profile 30. The EHP score indicate the extent of self-reported ill health on each of the 5 domains measured (Pain, Control and powerlessness, Social support, Emotional well-being, Self-image). Each scale is standardised on a scale of 0 - 100, where 0 indicates the best health status through to 100 worst health status. |
| General Self-Efficacy Scale | 8 weeks after randomization | The General Self-Efficacy Scale is a 10-item psychometric scale that is designed to assess optimistic self-beliefs to cope with a variety of difficult demands in life, Likert scale (1= Not at all true 2= Hardly true 3= Moderately true 4= Exactly true) |
| Insomnia Severity | 8 weeks after randomization | Total score from the 7-item Insomnia Severity Index where total score ranges from 0-28 and higher scores indicate greater severity of insomnia. |
| Days of sick-leave | 8 weeks after randomization | Number of days of sick-leave |
| Pain intensity | 16 weeks after start of TENS treatment | Pain intensity according to numeric rating scale (score from 0 to 10, where 0 is described as no pain and 10 as worst pain imaginable) with regard to endometriosis-related chronic pain |
| Physical activity | 16 weeks after start of TENS treatment | Minutes of physical activity per week at moderate and vigorous intensity physical activity (MVPA), minutes of sedentary behaviour (SED) assessed by accelerometry |
| Self-assessed physical activity | 16 weeks after start of TENS treatment | Minutes of physical activity per week (physical exercise and daily exercise) and minutes of sedentary behaviour per week. |
| Consumption of analgetics | 8 weeks after randomization | Consumption of primary and secondary analgetics including opioid consumption in morphine equivalent doses |
| Health Related Quality of Life (HRQL) according to SF36 | 8 weeks after randomization | Assessed with RAND Short Form 36 (SF36). The 36 items in the questionnaire are grouped into eight subscale scores: physical functioning, role limitations caused by physical problems, bodily pain, general health, energy/vitality, social functioning, role limitations caused by emotional problems and mental health. The subscale scores range from 0-100, the higher score, the better health related quality of life. |
| Health Related Quality of Life (HRQL) assessed with EQ-5D | 8 weeks after randomization | Assessed with EQ-5D-5L. The questionnaire comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Multidimensional Assessment of Interoceptive Awareness | 8 weeks after randomization | The Multidimensional Assessment of Interoceptive Awareness (MAIA) is an 8-scale state-trait questionnaire with 32 items to measure multiple dimensions of interoception by self-report. |
| Return to work | 8 weeks after randomization | Number of patients who return to work part time or full time. |
| Anxiety, depression | 8 weeks after randomization | Assessed with the Hospital Anxiety and Depression (HAD) scale. The scale consists of 14 items on a four-point response scale ranging from 0-3. Seven items for depression and 7 items for anxiety with a score range from 0-21. For each factor (anxiety or depression), the results are interpreted as follows: \< 8 points indicates within normal range, 8-10 points indicates possible and \>10 points indicates probable anxiety or depression. |
| Patient treatment satisfaction according to NRS | 8 weeks after randomization | Self-reported treatment satisfaction with regard to pain relief, how acceptable the patient finds the treatment and hospital care. Numeric rating scale (score from 0 to 10, where 0 is described as not satisfied at all and 10 as very satisfied) and numeric rating scale (score from 0 to 10, where 0 is described as not acceptable at all and 10 as very acceptable). |
Countries
Sweden
Contacts
Primary ContactPaulin Andréll, MD, PhD
Backup ContactCecilia Ögren, RN
Outcome results
None listed